This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
TheStreet Rating

10 Best Biotech Stocks for 2015

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks, by industry. The following biotech stocks are rated highest by our value-focused model. This list will be updated as upgrades and downgrades occur.

Equity Top: Biotechnology

Source: TheStreet Ratings

Best Investments for 2015

Biotechnology News

Biotech columnist Adam Feuerstein answers readers' questions about health care.
1/23/15 6:00AM
The J.P. Morgan Healthcare Conference is in the rear-view mirror, but issues, controversies and questions raised during the annual gathering of the biotech sector tribe will linger through the year.
1/20/15 10:18AM
Express Scripts CEO George Paz doesn't mince words about the need to cap specialty drug pricing during his talk Tuesday at the J.P. Morgan Healthcare Conference.
1/13/15 12:46PM
Aegerion slipped disclosure of the SEC probe into an regulatory filing last night.
1/13/15 9:12AM
Included in Bienaime's investor presentation is two slides making a direct data comparison between BioMarin's (soon to be) Duchenne muscular dystrophy drug drisapersen and Sarepta's competing DMD drug eteplirsen.
1/12/15 2:38PM
The timing of the Afrezza commercial launch is still a mystery following Sanofi's presentation.
1/12/15 1:35PM
Celgene CEO Bob Hugin just wrapped his presentation at the J.P. Morgan Healthcare Conference by reiterating 2017 financial guidance and offering new, longer-term guidance for 2020.
1/12/15 11:40AM
The company presents at the J.P. Morgan Healthcare Conference on Thursday.
1/12/15 9:47AM
Lung cancer is a larger commercial market opportunity for Bristol's Opdivo and Merck's Keytruda.
1/12/15 7:07AM
The company announced its 2015 business outlook on Sunday ahead of its presentation at the J.P. Morgan Healthcare Conference.
1/12/15 6:08AM
Roche's $1 billion-plus investment in Foundation Medicine aims to expand use of genetic testing to develop new, more effective drugs.
1/12/15 1:00AM
A successful rare-disease drug launch and the development of a second product made NPS an attractive takeout target.
1/12/15 12:15AM
TheStreet senior columnist Adam Feuerstein previews what to watch at the J.P. Morgan Healthcare Conference, which kicks off Monday in San Francisco.
1/9/15 3:11PM
Following a week of awareness raising through phone calls, Twitter and a Loncar guest appearance on CNBC, the number of JPM breakout session webcasts has increased significantly.
1/9/15 2:56PM
The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.
1/9/15 7:40AM

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs